Imlunestrant (1) – Inluriyo®
Breast cancer, ER+, HER2-, with an ESR1 mutation, progressive following prior endocrine therapy
Characteristics
| Start date | 15.03.2026 |
|---|---|
| Resolution | 03.09.2026 – active procedure |
| INN | Imlunestrant |
| Brand name | Inluriyo® |
| Pharm. company | Lilly Deutschland GmbH |
| G-BA Procedure ID | D-1313 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions